Estée Lauder Companies falls 4.1% after quarterly earnings beat and raised guidance

What happened

Estée Lauder Companies (EL) fell 4.1% on November 2, 2026, after fiscal first-quarter results beat estimates and management raised its fiscal 2027 outlook because of stronger organic sales and expanding margins. The stock closed at $104.77 after opening 2.8% above the previous close, and trading volume was 2.6 times its 20-day average. Management said organic sales grew 6% in the quarter and credited recent strategic initiatives, including its Beauty Reimagined program and its Profit Recovery and Growth Plan, for the improvement.

How big was the move

The one-day decline was 1.4 times a typical daily move for the stock and was 5.9 percentage points worse than the Consumer Defensive sector median, which rose 1.8% on the day. The S&P 500 fell 0.5% on the session and had fallen 1.8% over the prior five sessions; the stock itself fell 3.7% over the last five sessions. Market value stood at $39.58 billion.

The technical picture

The stock traded 1.0% above its 20-day moving average and 4.3% above its 50-day moving average, with the 50-day average above the 200-day average, a sign of an established uptrend. The stock had been above its 200-day average for 21 consecutive trading days and was 13.9% below its 52-week high. Momentum indicators were neutral, with a 14-day Relative Strength Index of 54. Over one month the stock rose 13.9% and over three months it rose 20.5%.

Fundamentals and valuation

For the four quarters through September 30, 2026, Estée Lauder reported revenue of $15.28 billion, up 5.8% from a year earlier and accelerating from one-quarter-earlier growth of 5.0%. Diluted earnings per share for that period were $1.00. Gross margin widened to 76.0% from 74.2% a year earlier, and operating margin improved to 12.0% from 0.9% a year earlier. Free-cash-flow margin was 9.9% and return on invested capital was 4.1%. The balance sheet showed net debt of 2.7 times EBITDA and the share count increased by 0.8% over one year.

Valuation measures put the stock at 104.8 times trailing earnings and 31.5 times expected forward earnings, with a free-cash-flow yield of 3.8%. The price to trailing earnings is higher than 73% of its own readings over the past five years; the five-year median is 67.3 times earnings. PromtFinance scores ranked the company strong on Quality at 80 and positive on Momentum and Revisions at 74 and 78, while Value and Stability read very weak at 9 and 14.

Earnings and analyst expectations

In its November 2, 2026, release, the company reported quarterly earnings per share of $0.72 versus $0.51 expected, a surprise of 42.0% above estimates; year-ago quarterly EPS was $0.32. That marked the fourteenth consecutive quarter beating estimates and the average surprise over the last four reports was 27.8% above estimates. Management raised fiscal 2027 organic sales guidance to a range of 4% to 5.5% and said it expects growth to be front-loaded relative to that full-year range. The typical two-day reaction after recent reports has been a 3.1% decline and the next scheduled report is February 4, 2027.

Analysts place a consensus price target of $108.69, 3.7% above the November 2 closing price, based on 46 analysts covering the stock. Forty-eight percent of ratings are Buy or Strong Buy and the consensus rating is Buy. Market sensitivity remained elevated with a beta of 1.59, indicating the stock tends to move more than the market.

What to watch

• November 2, 2026: reported quarterly EPS of $0.72 against $0.51 expected, 42.0% above estimates
• Management guidance: raised fiscal 2027 organic sales range to 4%–5.5% and said growth is expected to be front-loaded
• Fragrance category: rose about 19%–20% and delivered the strongest operating margin in the quarter
• Next report: February 4, 2027
• Trading: volume was 2.6 times its 20-day average on the session